Navigation Links
Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
Date:5/22/2013

SAN DIEGO, May 22, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective FLT3 inhibitor, will be presented at the Annual Meeting of the American Society of Clinical Oncology, held May 31 through June 4, 2013, at McCormick Place in Chicago.

Information about the abstracts, including presentation time and location, is listed below. Abstracts can be viewed online at http://abstracts2.asco.org/. Abstract No:
7023Title:Efficacy and Safety of Quizartinib (AC220) in Patients Aged > / = 70 Years with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia (AML)Presenter:Alexander Perl, M.D. (University of Pennsylvania)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7012Title:High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation (HSCT) with Quizartinib (AC220) in Patients with FLT3 ITD Positive or Negative Relapsed/Refractory AML After Second Line Chemotherapy or Previous Bone Marrow TransplantPresenter:Jorge Cortes, M.D. (MD Anderson Cancer Center, University of Texas)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m. to noon (CDT) in S 405Presented:Saturday, June 1, noon to 1 p.m. (CDT) in S 406Abstract No:
7021Title:Quizartinib (AC220) Produces High Response Rates and Long Term Survival in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid LeukemiaPresenter:Giovanni Martinelli, M.D., Ph.D. (University of Bologna School of Medicine)Session:Leukemia, Myelodysplasia, and TransplantationOn Display:Saturday, June 1, 8 a.m.
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
2. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
3. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
4. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
5. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
6. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
7. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
10. Neurocrine Biosciences Reports First Quarter 2012 Results
11. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... HealthSouth Corporation (NYSE: HLS ) announced today ... dividend of $16.25 per share on its 6.5% Series A ... holders of record on Oct. 1, 2010. ... rehabilitative healthcare services. Operating in 26 states across the country ...
... Pharmacy announced today they have earned a position of 554 on ... companies in America. "We,re proud to be recognized by ... in the nation, but if you dig a little deeper into ... Phil Hagerman, President and CEO of Diplomat. The details Hagerman refers ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic ... company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations ... clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Precision Aesthetics ... eight years. It was also the first provider of Exilis non-surgical fat reduction ... sought after procedures it has attracted a large International clientele. Many patients travel ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... his third annual "Grandpa,s Road Trip" with the NxStage(R) System One(TM). ... provides Mr. Wells the opportunity to fit hemodialysis therapy into his ...
... , SILVER SPRING, Md., Sept. 18 The U.S. ... O Plus assay, as a screening tool designed to detect the presence ... that run on the fully automated Abbott Prism System. , , ... There are two types of HIV. HIV type 1 consists ...
... LOUDOUN COUNTY, Va., Sept. 18 On Sunday, ... wellness partner GlaxoSmithKline, and Men,s Health Network (MHN), will recognize ... awareness ribbons and disease awareness information cards to fans prior ... FedExField. Led by MHN staff, volunteers from GlaxoSmithKline, Sigma Phi ...
... abuse among those who could drink before 21 , FRIDAY, ... a place and time when they could legally buy alcohol ... alcoholics or have a drug problem, even well into adulthood, ... Dr. Karen Norberg, a research instructor in psychiatry at Washington ...
... , , , ... pioneer and leader in the development of Optical Coherence Tomography ... will showcase its advanced FD-OCT(TM) technology, the C7-XR(TM) imaging system, ... CA starting Monday, September 21 through Friday, September 25, 2009. ...
... less cost, study suggests , FRIDAY, Sept. 18 (HealthDay News) ... into signs of heart disease by using cardiac CT scans ... CT scans use X-rays to create cross-sectional images of the ... arteries, but it,s hard to tell if they,re actually preventing ...
Cached Medicine News:Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Men's Health Network, The Washington Redskins and GlaxoSmithKline Team Up for September's Prostate Cancer Awareness Month 2Health News:Lower Drinking Age Linked to Later-Life Problems 2Health News:Lower Drinking Age Linked to Later-Life Problems 3Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 2Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 3Health News:Researchers Perfect the View of Heart Disease 2
Bayonet fine, smooth - 1/box....
Blunt, with attached cable for Valleylab and other brands generators....
Bipolar hand activated forceps....
Blunt, 20 cm long....
Medicine Products: